To estimate the impact of PD-L1 immunostaining in tumor and inflammatory cells on patient prognosis we analyzed the relationship between PD-L1 immunostaining and OS (time between cystectomy and death) in 512 patients with muscle-invasive carcinomas who had never been treated with CPIs. The gene discussed is CD274; the disease is neoplasm.